contact  |  disclaimer  |  intranet

 

  Home

 

  

  SARS

 

   • Introduction

 • Outbreak

 • 2003 SARS epidemic

 • Virus hunting

 • Coronaviruses

 • Virus evolution

 • Control

 • Novel coronaviruses

 • Future research

 

 

     

SARS-DTV consortium

  (Documents from the year  2004

  when SARS-DTV research started)

 • SARS-DTV research plan

 • SARS-DTV: who we are

 • SARS-DTV leaflet

 • Contact information

  

  SARS-DTV publications

  (2004-2008)

 

  SARS-DTV final report

  (2008)

 

 

 

  Useful links

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Last update: October 2004

 

  

 

 

 

 

 

 

 

Outline of the SARS-DTV Project

 

SARS-DTV is a
Scientific Support to Policies Research Project

financed by

the European Commission
within the
6th Framework Programme

 

The SARS-DTV Consortium is composed of 15 research partners from six European countries, China and Taiwan. It includes three Small and Medium-size Enterprises (SMEs). The Coordinator is the Department of Medical Microbiology of Leiden University Medical Center (LUMC), the Netherlands.

The SARS-DTV Steering Committee is composed of: Prof. Willy Spaan (LUMC; coordinator and leader of the work package Diagnostics and Standardisation), Prof. Eric Snijder (LUMC; deputy-coordinator and leader of the work package Molecular Targets), Dr. Jan ter Meulen (Crucell; leader of the work package Correlates of Humoral and Cellular protection), Prof. Stuart Siddell (Bristol; leader of the work package Model Systems), Dr. Jerome Weinbach (Inserm-Transfert; project manager).

 

Overview:

SARS-DTV forms an integrated research consortium across Europe and Asia. The overall objective of the project is to contribute to the development of candidate anti-SARS drugs, vaccines and diagnostic assays.
The SARS-DTV Network’s major focuses:

  • Identify molecular targets for antiviral therapy
  • Develop an improved understanding of the immune response to SARS antibody and cell-mediated responses
  • Formulate systems for testing the inhibition of viral replication
  • Develop rapid diagnostic tests that will provide results in less than 30 minutes

Contribution to policy development:

  • The development of an improved surveillance capability in high-risk areas will provide an earlier indication of potential SARS epidemics
  • An enhanced capability to prevent and control SARS infections
  • An improved ability to undertake SARS directed research through an expanded pool of trained scientists

Main project deliverables:

  • Inhibitors of SARS virus replication – months 6 to 36 
  • Optimisation of monoclonal antibodies for use in diagnostic assays – month 12
  • Data on the safety and efficacy of selected antiviral compounds in the mouse model – month 36
  • Rapid immunochromatography assay for the detection of SARS virus – month 30
  • Plan for using and disseminating knowledge – month 36

Dissemination:

  • Organise and update a public domain webpage
  • Establish connections with other EU-funded SARS related networks
  • Develop connections with patient organisations and advocacy groups
  • Design a poster aimed at a non-specialist audience summarising the main activities
  • Produce a brochure summarising the main achievements
  • Undertake presentations at international meetings